ResearcherBanner MD Anderson Cancer CenterActive in the last 2 years
Madappa N. Kundranda
Matched on ORCID iD 0000-0002-9237-2666; OpenAlex author ID A5003240554. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 14
2017: 1 paper · 2018: none · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 6
- KRAS Inhibition in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/jcm15020873↗
- Skeletal metastases in advanced pancreatic ductal adenocarcinoma: a retrospective analysis. Last author DOI 10.21037/jgo-20-361↗
- Infection Masquerading as Recurrence of Pancreatic Ductal Adenocarcinoma: A Cautionary Tale. Co-author DOI 10.7759/cureus.17010↗
- Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine i… Co-author DOI 10.1016/j.annonc.2019.09.004↗
- Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel a… Co-author DOI 10.1016/j.annonc.2020.05.011↗
- Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma. First author DOI 10.3390/ijms18030667↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Roshini Pradeep · 1 shared paper, 2026 · strength 0.36
- John C. S. Chang · 2 shared papers, 2017–2021 · strength 0.29
- Andrew H. Ko · 2 shared papers, 2020 · strength 0.18
- Paper Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine… DOI 10.1016/j.annonc.2019.09.004↗
- Paper Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel… DOI 10.1016/j.annonc.2020.05.011↗
- Syed Farhan Zafar · 2 shared papers, 2020 · strength 0.18
- Paper Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine… DOI 10.1016/j.annonc.2019.09.004↗
- Paper Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel… DOI 10.1016/j.annonc.2020.05.011↗
- Fernando Rivera · 2 shared papers, 2020 · strength 0.18
- Paper Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine… DOI 10.1016/j.annonc.2019.09.004↗
- Paper Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel… DOI 10.1016/j.annonc.2020.05.011↗
- David J. Watkins · 2 shared papers, 2020 · strength 0.18
- Paper Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine… DOI 10.1016/j.annonc.2019.09.004↗
- Paper Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel… DOI 10.1016/j.annonc.2020.05.011↗
- Uwe Pelzer · 2 shared papers, 2020 · strength 0.18
- Paper Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine… DOI 10.1016/j.annonc.2019.09.004↗
- Paper Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel… DOI 10.1016/j.annonc.2020.05.011↗
- Hana Algül · 2 shared papers, 2020 · strength 0.18
- Paper Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine… DOI 10.1016/j.annonc.2019.09.004↗
- Paper Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel… DOI 10.1016/j.annonc.2020.05.011↗
- Johanna C. Bendell · 2 shared papers, 2020 · strength 0.18
- Paper Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine… DOI 10.1016/j.annonc.2019.09.004↗
- Paper Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel… DOI 10.1016/j.annonc.2020.05.011↗
- J. Marc Pipas · 2 shared papers, 2020 · strength 0.18
- Paper Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine… DOI 10.1016/j.annonc.2019.09.004↗
- Paper Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel… DOI 10.1016/j.annonc.2020.05.011↗
- Sowbharnika Arivazhagan · 1 shared paper, 2021 · strength 0.17
- Marshall Patrick Stagg · 1 shared paper, 2021 · strength 0.17
- Akshjot Puri · 1 shared paper, 2021 · strength 0.14
- Tomislav Dragovich · 1 shared paper, 2021 · strength 0.14
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.